, Volume 17, Supplement 1, pp 23–28 | Cite as

Current Status and Replies to Frequently Posed Questions on Atovaquone Plus Proguanil (Malarone® ) for the Prevention of Malaria

  • Kevin C. Kain
Review Article


Each year at least 30 000 Western travellers acquire malaria and approximately 1–4% of those who acquire Plasmodium falciparum malaria will die as a result of infection. Almost all cases and fatalities are preventable with the use of measures to reduce mosquito bites and appropriate chemoprophylaxis for those at high risk of infection. There are currently a limited number of licensed drugs available to prevent malaria in travellers. New effective and well tolerated agents are urgently needed because of increasing resistance to antimalarials such as chloroquine and proguanil, and real and perceived intolerance to standard drugs such as mefloquine. A newly licensed antimalarial (atovaquone plus proguanil; Malarone®1) compares favourably with other drug options, although some prescribers may be unfamiliar with the specific advantages and disadvantages of this antimalarial. This article reviews recent clinical experience and randomised controlled trial data in order to address frequently asked questions about this new combination drug.



This work was supported by the Canadian Institutes of Health Research (CIHR, MT-13721). K.C. Kain is supported by a Career Scientist Award from the Ontario Ministry of Health and a Canada Research Chair (CIHR). K.C. Kain is on the CME Speakers Bureau for GlaxoSmithKline, Pfizer and Roche.


  1. 1.
    World Health Organization (WHO). The world report 1999: making a difference. Geneva: WHO, 1999Google Scholar
  2. 2.
    Ryan ET, Kain KC. Health advice and immunizations for travelers. N Engl J Med 2000; 342: 1716–25PubMedCrossRefGoogle Scholar
  3. 3.
    Kain KC. Prophylactic drugs for malaria: why do we need another one? J Travel Med 1999; 6Suppl. 1: S2–7Google Scholar
  4. 4.
    Greenberg AE, Lobel HO. Mortality from Plasmodium Falciparum malaria in travellers from the United States, 1959 to 1987. Ann Intern Med 1990; 113: 326–7PubMedGoogle Scholar
  5. 5.
    Newman RD, Barber AM, Roberts J, et al. Malaria surveillance: United States, 1999. MMWR Surveill Summ 2002; 51(1): 15–28PubMedGoogle Scholar
  6. 6.
    Bradley DJ, Warhurst DC, Blaze M, et al. Malaria imported into the United Kingdom in 1996. Euro Surveill 1998; 3: 40–2PubMedGoogle Scholar
  7. 7.
    Kain KC, Macpherson DW, Kelton T, et al. Malaria deaths in visitors to Canada and in Canadian travellers: a case series. CMAJ 2001; 164: 654–9PubMedGoogle Scholar
  8. 8.
    Miihlberger N, Jelinek T, Behrens RH, et al. Age is a risk factor for severe manifestations and fatal outcome in European patients with falciparum malaria: observations from TropNetEurop- and SIMPID-surveillance data [abstract MOP5002]. Program and abstracts of the 3rd European Conference on Tropical Medicine and International Health. Acta Tropica 2002; 83: 531Google Scholar
  9. 9.
    Centers for Disease Control and Prevention (CDC). Health information for international travel: 2001–2002. Atlanta: US Department of Health and Human Services, 2001Google Scholar
  10. 10.
    Canadian recommendations for the prevention and treatment of malaria among international travellers. Committee to Advise on Tropical Medicine and Travel (CATMAT), Laboratory for Disease Control. Can Commun Dis Rep 2000; 26Suppl. 2: i–vi, 1-42Google Scholar
  11. 11.
    World Health Organization (WHO). International travel and health 2002. Geneva: WHO, 2002Google Scholar
  12. 12.
    Hay SI, Cox J, Rogers DJ, et al. Climate change and the resurgence of malaria in the East African highlands. Nature 2002; 415: 905–9PubMedCrossRefGoogle Scholar
  13. 13.
    Ohrt C, Ritchie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. Ann Intern Med 1997; 126: 963–72PubMedGoogle Scholar
  14. 14.
    Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet 1993; 341: 1299–303PubMedCrossRefGoogle Scholar
  15. 15.
    Hill DR, Behrens RH, Bradley DJ. The risk of malaria in travellers to Thailand. Trans R Soc Trop Med Hyg 1996; 90: 680–1PubMedCrossRefGoogle Scholar
  16. 16.
    Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002; 347(1): 13–8PubMedCrossRefGoogle Scholar
  17. 17.
    Soto J, Medina F, Dember N, et al. Efficacy of permethrin-impregnated uniforms in the prevention of malaria and leishmaniasis in Colombian soldiers. Clin Infect Dis 1995; 21: 599–602PubMedCrossRefGoogle Scholar
  18. 18.
    Ryan ET, Wilson M, Kain KC. Illness after international travel. N Engl J Med 2002; 347: 505–16PubMedCrossRefGoogle Scholar
  19. 19.
    World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000; 94Suppl. 1: S1–S90CrossRefGoogle Scholar
  20. 20.
    Kain KC, Shanks GD, Keystone JS. Malaria chemoprophylaxis in an age of drug resistance I: currently recommended drug regimens. Clin Infect Dis 2001; 33: 226–34PubMedCrossRefGoogle Scholar
  21. 21.
    Shanks GD, Kain KC, Keystone JS. Malaria chemoprophylaxis in an age of drug resistance II: drugs that may be available in the future. Clin Infect Dis 2001; 33: 381–5PubMedCrossRefGoogle Scholar
  22. 22.
    Berman JD, Nielsen R, Chulay JD, et al. Causal prophylactic efficacy of atorvaquone (Malarone) in a human challenge model. Trans R Soc Trop Med Hyg 2001; 95: 429–32PubMedCrossRefGoogle Scholar
  23. 23.
    Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 1999; 43: 1334–9PubMedGoogle Scholar
  24. 24.
    Beerahee M, Clarke P, Overbosch D, et al. Prophylaxis with Malarone (atovaquone and proguanil hydrochloride) in non-immune subjects 65 years age and older. Proceedings of the Third European Congress on Tropical Medicine and International Health; 2002 Sep 8–11; Lisbon, PortugalGoogle Scholar
  25. 25.
    Product Information. Malarone brand of atovaquone and proguanil hydrochloride tablets. Research Triangle Park: GlaxoSmithKline, 2002Google Scholar
  26. 26.
    Shapiro TA, Ranasinha CD, Kumar N, et al. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am J Trop Med Hyg 1999; 60: 831–6PubMedGoogle Scholar
  27. 27.
    Shanks GD, Gordon DM, Klotz FW, et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 1998; 27: 494–9PubMedCrossRefGoogle Scholar
  28. 28.
    Lell B, Luckner D, Ndjave M, et al. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351: 709–13PubMedCrossRefGoogle Scholar
  29. 29.
    Sukwa TY, Mulenga M, Chisdaka N, et al. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999; 60: 521–5PubMedGoogle Scholar
  30. 30.
    Hogh B, Clarke P, Camus D, et al. Atovaquone/proguanil versus chloroquine/proguanil for malaria prophylaxis in non-immune travellers: results from a randomised, double-blind study. Lancet 2000; 356: 1888–94PubMedCrossRefGoogle Scholar
  31. 31.
    Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in non-immune travellers: results from a randomised, double-blind study. Clin Infect Dis 2001; 33: 1015–21PubMedCrossRefGoogle Scholar
  32. 32.
    Ling J, Baird JK, Fryauff DJ, et al. Randomized, double-blind, placebo-controlled evaluation of Malarone for prophylaxis of P. vivax and P. falciparum malaria in non-immune transmigrants to Papua. Clin Infect Dis 2002; 35: 825–33PubMedCrossRefGoogle Scholar
  33. 33.
    van der Berg JD, Duvenage CS, Roskeil NS, et al. Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum in South Africa. Clin Ther 1999; 21: 741–9PubMedCrossRefGoogle Scholar
  34. 34.
    Faucher JF, Binder R, Missinou MA, et al. Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis 2002; 35: 1147–54PubMedCrossRefGoogle Scholar
  35. 35.
    Nasveld PE, Edstein MD, Kitchener SJ, et al. Comparison of the effectiveness of atovaquone/proguanil combination and doxycycline in the chemoprophylaxis of malaria in Australian Defence Force personnel [abstract 16]. Program and abstracts of the 49th Annual Meeting of the American Society of Tropical Medicine and Hygiene; 2002 Oct 29–Nov 2; Houston, Texas: 139Google Scholar
  36. 36.
    Camus D, Malvy D, Schilthuis H, et al. Atovaquone/proguanil versus chloroquine/proguanil or mefloquine in clinical trials of non-immune paediatric travellers 11–40kg. Proceedings of the Third European Congress on Tropical Medicine and International Health; 2002 Sep 8–11; Lisbon, PortugalGoogle Scholar
  37. 37.
    van Vugt M, Leonardi E, Phaipun L, et al. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. Clin Infect Dis 2002; 35: 1498–504PubMedCrossRefGoogle Scholar
  38. 38.
    Looareesuwan S, Viravan C, Webster HK, et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996; 54: 62–6PubMedGoogle Scholar
  39. 39.
    Korsinczky M, Chen N, Kotecka B, et al. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 2000; 44: 2100–8PubMedCrossRefGoogle Scholar
  40. 40.
    Fivelman QL, Butcher GA, Adagu IS, et al. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar J 2002; 1: 1PubMedCrossRefGoogle Scholar
  41. 41.
    Schwartz E, Bujanover S, Kain KC. Genetic confirmation of Atovaquone-proguanil (Malarone™) resistant Plasmodium falciparum malaria acquired by a non-immune traveler to East Africa. Clin Infect Dis 2003. In pressGoogle Scholar
  42. 42.
    Schlagenhauf P, Tschopp A, Johnson R, et al. Randomised, double-blind, fourarm study of the adverse event profiles of malaria chemoprophylaxis in non-immune travelers to sub-Saharan Africa [abstract 568]. Am J Trop Med Hyg 2002; 67: 354–5Google Scholar
  43. 43.
    Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immu-nosuppression on malaria parasitemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356: 1051–6PubMedCrossRefGoogle Scholar
  44. 44.
    Lee BL, Tauber MG, Sadler B, et al. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clin Pharmacol Ther 1996; 59: 14–21PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Kevin C. Kain
    • 1
  1. 1.Tropical Disease Unit, Toronto General HospitalUniversity Health Network, University of TorontoOntarioCanada

Personalised recommendations